Canna~Fangled Abstracts

Cannabidiol Induces Cell Death in Human Lung Cancer Cells and Cancer Stem Cells

By November 17, 2021November 29th, 2021No Comments
. 2021 Nov 17;14(11):1169.

doi: 10.3390/ph14111169.

Hussein Hamad 1, Birgitte Brinkmann Olsen 1 2
Affiliations 

Abstract

Currently, there is no effective therapy against lung cancer due to the development of resistance. Resistance contributes to disease progression, recurrence, and mortality. The presence of so-called cancer stem cells could explain the ineffectiveness of conventional treatment, and the development of successful cancer treatment depends on the targeting also of cancer stem cells. Cannabidiol (CBD) is a cannabinoid with anti-tumor properties. However, the effects on cancer stem cells are not well understood. The effects of CBD were evaluated in spheres enriched in lung cancer stem cells and adherent lung cancer cells. We found that CBD decreased viability and induced cell death in both cell populations. Furthermore, we found that CBD activated the effector caspases 3/7, increased the expression of pro-apoptotic proteins, increased the levels of reactive oxygen species, as well as a leading to a loss of mitochondrial membrane potential in both populations. We also found that CBD decreased self-renewal, a hallmark of cancer stem cells. Overall, our results suggest that CBD is effective against the otherwise treatment-resistant cancer stem cells and joins a growing list of compounds effective against cancer stem cells. The effects and mechanisms of CBD in cancer stem cells should be further explored to find their Achilles heel.

 

Keywords: apoptosis, cancer stem cells, cannabidiol, lung cancer, reactive oxygen species

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1

Figure 2

Figure 3

Figure 4

Figure 4

Figure 5

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. – DOI – PubMed
    1. Uramoto H., Tanaka F. Recurrence after surgery in patients with NSCLC. Transl. Lung Cancer Res. 2014;3:242–249. – PMC – PubMed
    1. Tulpule A., Bivona T.G. Acquired resistance in lung cancer. Annu. Rev. Cancer Biol. 2020;4:279–297. doi: 10.1146/annurev-cancerbio-030419-033502. – DOI
    1. Shien K., Toyooka S., Yamamoto H., Soh J., Jida M., Thu K.L., Hashida S., Maki Y., Ichihara E., Asano H., et al. Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res. 2013;73:3051–3061. doi: 10.1158/0008-5472.CAN-12-4136. – DOI – PMC – PubMed
    1. Liu Y.P., Yang C.J., Huang M.S., Yeh C.T., Wu A.T., Lee Y.C., Lai T.C., Lee C.H., Hsiao Y.W., Lu J., et al. Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. Cancer Res. 2013;73:406–416. doi: 10.1158/0008-5472.CAN-12-1733. – DOI – PubMed

Leave a Reply